Eliminating OVD need via FLACS

Article

Phacoemulsification and intraocular lens implantation can be performed without an ophthalmic viscosurgical device (OVD) by using a femtosecond laser-assisted procedure (FLACS), according to researchers from the Institute for Vision Science, Ruhr University Eye Clinic, Bochum, Germany.

Phacoemulsification and intraocular lens implantation can be performed without an ophthalmic viscosurgical device (OVD) by using a femtosecond laser-assisted procedure (FLACS), according to researchers from the Institute for Vision Science, Ruhr University Eye Clinic, Bochum, Germany.

According to the researchers, performing FLACS without OVD poses no additional risk to the corneal endothelium compared with patients whose surgery was performed with standard phacoemulsification using OVD.

Reporting in the Journal of Refractive Surgery, the researchers conducted a prospective, randomized, single-centre trial of 74 eyes in 37 patients diagnosed as having significant cataracts in both eyes.

 In all of the patients, one eye was randomized to receive standard phacoemulsification with OVD. The other eye was treated with a femtosecond laser, and the subsequent manual part of the procedure was performed without using OVD. The patients were followed for 6 months.

The researchers found that among all the eyes, there were no significant differences in:

• major complications (none in either group)

• overall surgery time (non-OVD: 375 ± 81 seconds; OVD: 362 ± 43 seconds)

• the quantity of fluid passing through the eyes (non-OVD: 187 ± 35 mL; OVD: 186 ± 27 mL)

• endothelial cell loss after 6 months (non-OVD: −2.4%; OVD: −2.7%)

 

• central corneal thickness at 1 week postoperatively (non-OVD: 575 ± 45 µm; OVD: 573 ± 46 µm;)

• corrected distance visual acuity (logMAR non-OVD: 0.024; OVD: 0.038).

The researchers added that at 1 day post-surgery, 1 patient in the non-OVD group experienced intraocular pressure >25 mmHg, compared to 3 patients in the OVD group.

 

To read the abstract of the study, click here

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.